cART

December 9, 2015May 13, 2016

Non-Hodgkin Lymphoma Study of Novartis’ T-cell Therapy Shows Early Efficacy

News

Novartis has released findings from a Phase 2a study evaluating the safety and efficacy of its novel chimeric antigen receptor T-cell (CART) immunotherapy CTL019 in two types of relapsed or refractory non-Hodgkin Lymphoma. The data was presented ... Read more

September 15, 2015September 15, 2015

Classical Hodgkin’s Lymphoma More Prevalent in Treated HIV Patients

News

Individuals with human immunodeficiency virus (HIV) seem to have higher rates of lymphoma development, especially grade B-non Hodgkin lymphomas (NHL). However, these lymphomas, which are also the most common types ... Read more

August 21, 2015August 21, 2015

HIV-Associated Hodgkin’s Lymphoma Patients Respond Similarly To Their Non-HIV Counterparts Under cART & ABVD Therapy

News

Recently conducted research by Caroline Besson, MD, PhD, division of cancer epidemiology and genetics at the National Cancer Institute, suggests that patients with Hodgkin’s Lymphoma (HL) associated with HIV respond ... Read more